Published in Curr Diab Rep on February 01, 2011
Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol (2013) 1.16
Metabolic syndrome in hypertensive patients: An unholy alliance. World J Cardiol (2014) 0.78
An approach to the etiology of metabolic syndrome. Colomb Med (Cali) (2013) 0.77
Vagus Nerve Stimulation Improves Cardiac Function by Preventing Mitochondrial Dysfunction in Obese-Insulin Resistant Rats. Sci Rep (2016) 0.76
Resistant Hypertension and Sleep Duration among Blacks with Metabolic Syndrome MetSO. J Sleep Disord Treat Care (2016) 0.75
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med (2009) 2.25
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem (2006) 1.62
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int (2013) 1.38
The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med (2011) 1.35
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology (2007) 1.31
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension (2008) 1.23
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology (2013) 1.15
Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol (2011) 1.12
Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology (2007) 1.11
The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) (2013) 1.06
Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr (2008) 1.06
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol (2011) 1.03
Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology (2010) 1.03
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. Cardiorenal Med (2011) 1.01
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism (2009) 1.00
Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 0.99
Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol (2007) 0.99
Inhibition of nitric oxide synthase evokes central sympatho-excitation in healthy humans. J Physiol (2009) 0.98
Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). Curr Diab Rep (2011) 0.98
Hypertension and insulin resistance. Hypertension (2009) 0.98
The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci (2005) 0.95
Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer. Cardiorenal Med (2012) 0.94
Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol (2005) 0.93
Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology (2014) 0.93
The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep (2010) 0.93
Indices of obesity and cardiometabolic risk. Hypertension (2011) 0.92
The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci (2005) 0.92
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens (2012) 0.91
Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats. Am J Nephrol (2010) 0.90
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 0.89
Antihypertensive medications and their effects on lipid metabolism. Curr Diab Rep (2008) 0.88
Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus. Cardiorenal Med (2011) 0.87
Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr (2006) 0.87
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept (2012) 0.87
DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring) (2014) 0.87
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol (2012) 0.87
Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2012) 0.86
Acute Cardiac Tamponade: An Unusual Cause of Acute Renal Failure. Cardiorenal Med (2012) 0.86
DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes. Cardiorenal Med (2013) 0.86
Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin North Am (2013) 0.86
The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. Cardiorenal Med (2011) 0.85
Hypertension in Cardiovascular and Kidney Disease. Cardiorenal Med (2011) 0.85
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag (2009) 0.85
The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. J Clin Endocrinol Metab (2012) 0.84
Novel role for the incretins in blood pressure regulation. Curr Opin Nephrol Hypertens (2012) 0.84
Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms. Cardiorenal Med (2012) 0.84
Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Transl Res (2009) 0.83
Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2005) 0.83
Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism (2011) 0.83
Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol (2006) 0.82
Anemia and chronic kidney disease: making sense of the recent trials. Rev Recent Clin Trials (2012) 0.82
The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. Cardiorenal Med (2013) 0.82
Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. Curr Diab Rep (2007) 0.82
Gestational Diabetes and the Offspring: Implications in the Development of the Cardiorenal Metabolic Syndrome in Offspring. Cardiorenal Med (2012) 0.82
The Role of Team-Based Care Involving Pharmacists to Improve Cardiovascular and Renal Outcomes. Cardiorenal Med (2012) 0.82
Intraperitoneal drug therapy: an advantage. Curr Clin Pharmacol (2010) 0.81
Tissue-specific expression of GLP1R in mice: is the problem of antibody nonspecificity solved? Diabetes (2014) 0.81
Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Am J Nephrol (2011) 0.81
Type 2 diabetes in older people; the importance of blood pressure control. Curr Cardiovasc Risk Rep (2013) 0.79
Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich) (2009) 0.79
Therapy of obese patients with cardiovascular disease. Curr Opin Pharmacol (2013) 0.79
Chronic kidney disease and cardiovascular risk. J Am Soc Hypertens (2010) 0.78
Obesity and heart failure as a mediator of the cerebrorenal interaction. Contrib Nephrol (2013) 0.78
Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). BMC Nephrol (2012) 0.78
Use of Metformin in Patients with Kidney and Cardiovascular Diseases. Cardiorenal Med (2011) 0.78
Basic science: Pathophysiology: the cardiorenal metabolic syndrome. J Am Soc Hypertens (2014) 0.78
Outcomes of carotid revascularization in patients with chronic kidney disease. Adv Chronic Kidney Dis (2008) 0.77
Over-nutrition contributes to tubulointerstitial fibrosis by targeting nutrient-sensing kinases: role for the mTOR/S6K pathway. Cell Cycle (2012) 0.77
Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. Expert Opin Pharmacother (2005) 0.77
Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome). Cardiorenal Med (2011) 0.77
Bioabsorbable coronary stents--are these the next big thing in coronary angioplasty? Recent Pat Cardiovasc Drug Discov (2010) 0.77
An Emerging Role for Understanding Orthostatic Hyp'er'tension in the Cardiorenal Syndrome. Cardiorenal Med (2011) 0.77
Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. Mol Cell Endocrinol (2013) 0.76
Update on the role of rituximab in kidney diseases and transplant. Expert Opin Biol Ther (2011) 0.76
The kaliuretic impact of cicletanine compared to hydrochlorothiazide. J Hypertens (2012) 0.75
Diabetes: Aspirin and prevention of diabetes still a topic of debate. Nat Rev Endocrinol (2009) 0.75
Obesity, insulin resistance, and nocturnal systolic blood pressure. Hypertension (2008) 0.75
Metabolic impact of adding a thiazide diuretic to captopril. Hypertension (2013) 0.75
Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket. Am J Physiol Renal Physiol (2013) 0.75
Role of Growth Hormone Deficiency and Treatment in Chronic Kidney Disease. Cardiorenal Med (2011) 0.75
Chronic kidney disease and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2006) 0.75
Micro vs. macrovascular reactivity in insulin resistance: the debate reignited. Am J Hypertens (2010) 0.75
Is there a role for the incretin system in blood pressure regulation? Curr Hypertens Rep (2014) 0.75
Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD. Clin J Am Soc Nephrol (2012) 0.75
Is it time to target prehypertension. Cardiovasc Ther (2010) 0.75
Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. J Clin Lipidol (2008) 0.75
A decade after the KDOQI CKD guidelines: impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2012) 0.75